Revenue: As of FY2025 Q1, the actual value is USD 0.EPS: As of FY2025 Q1, the actual value is USD -1.12.EBIT: As of FY2025 Q1, the actual value is USD -4.209 M.<h3>Segment Revenue</h3><ul><li>Total Revenues: For the three months ended March 31, 2025, Zivo Bioscience, Inc. recorded no revenue, compared to $35,720 for the same period in 2024, due to no product orders from the exclusive distributor.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended March 31, 2025, was $4,211,188, compared to $1,278,486 for the same period in 2024.</li><li>General and Administrative Expenses: Increased to $1,439,552 in 2025 from $975,574 in 2024, primarily due to higher professional fees.</li><li>Research and Development Expenses: Increased significantly to $2,769,236 in 2025 from $312,767 in 2024, largely due to costs associated with extinguishing Participation Agreements.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was - $1,430,238 for the three months ended March 31, 2025, compared to - $1,699,118 for the same period in 2024.</li><li>Financing Activities: Generated $404,985 in 2025, a decrease from $1,563,379 in 2024, due to the absence of funds raised through sales of common stock in 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Zivo Bioscience, Inc. plans to continue developing bioactive compounds from its proprietary algal culture, targeting diseases such as poultry coccidiosis and bovine mastitis, and seeks strategic partners for late-stage development and commercialization.</li><li>Non-Core Business: The company is exploring additional indications such as avian influenza and canine joint health, pending additional funding.</li><li>Funding Requirements: The company acknowledges substantial doubt about its ability to continue as a going concern and requires approximately $5 million in cash over the next 12 months to fund basic operations, excluding R&amp;D initiatives.</li></ul>

ZIVO BIOSCIENCE INC | 10-Q: FY2025 Q1 Revenue: USD 0